Sort
82,697 grants matching “vaccine development”
SPORE in Head and Neck Cancer
$2,319,298Johns Hopkins University · P50 · FY2005 · CA
SPORE in Head and Neck Cancer
$2,319,298Johns Hopkins University · P50 · FY2004 · CA
SPORE in Head and Neck Cancer
$2,319,298Johns Hopkins University · P50 · FY2003 · CA
Flow Cytometry Core
$2,319,001Stephen Perfetto · National Institute Of Allergy And Infectious Diseases · ZIC · FY2023 · AI
Acute HIV Infection: Implications for vaccine design
$2,318,714Marcus Altfeld · Massachusetts General Hospital · P01 · FY2008 · AI
Nucleic Acid-Based Nanoconstructs for the Treatment of Cancer
$2,318,682Chad A. Mirkin · Northwestern University At Chicago · U54 · FY2017 · CA
DENVER AUTOIMMUNITY CENTER OF EXCELLENCE
$2,318,155University Of Colorado Denver · U19 · FY2000 · AI
Discovery of novel Henipavirus inhibitors
$2,317,735Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2023 · AI
Nanomaterials for engineering protection in the genital mucosa
$2,317,500Kim A. Woodrow · University Of Washington · DP2 · FY2012 · HD
Development of combination immunotherapies for atherosclerotic inflammation
$2,317,500Evan Alexander Scott · Northwestern University · DP2 · FY2015 · HL
Units for HIV/AIDS Clinical Trials Networks
$2,317,443Michael C Keefer · University Of Rochester · U01 · FY2009 · AI
Mayo Clinic Breast Cancer SPORE
$2,317,281Matthew Philip Goetz · Mayo Clinic Rochester · P50 · FY2022 · CA
Development of a Recombinant Tuberculosis Vaccine
$2,316,340Corixa Corporation · UC1 · FY2000 · AI
Center for Cancer Immunology and Immunotherapy (CCII)
$2,316,025Jun Yan · University Of Louisville · P20 · FY2022 · GM
Robust T-cell Immunity to Influenza in Human Populations
$2,315,646Bloodcenter Of Wisconsin, Inc. · U19 · FY2005 · AI
Mayo Clinic Breast Cancer SPORE
$2,314,870Matthew Philip Goetz · Mayo Clinic Rochester · P50 · FY2024 · CA
Optimization of HIV vaccines for the induction of cross-reactive antibodies
$2,313,313Shan Lu · Univ Of Massachusetts Med Sch Worcester · U19 · FY2009 · AI
Paramyxoviruses as Vaccine Vectors Against Highly Pathogenic Viruses
$2,313,167Peter Leon Collins · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
CORE NICHD NETWORK CLINICAL SITE SUPPORT FOR IMPAACT RELATED STUDIES
$2,312,964Barbara Driver · Westat, Inc. · N01 · FY2022 · HD
Tumor microenvironment in CLL and MCL: pathogenesis, targets, and therapy
$2,312,651Adrian U Wiestner · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL
Providence/Boston Center for AIDS Research (CFAR)
$2,311,717Susan Cu-Uvin · Miriam Hospital · P30 · FY2022 · AI
NIAID Microbiome Program
$2,311,400Yasmine Belkaid · National Institute Of Allergy And Infectious Diseases · ZIC · FY2021 · AI
Pitt-Ohio State Clinical Trials Unit
$2,310,879Sharon Riddler · University Of Pittsburgh At Pittsburgh · UM1 · FY2024 · AI
GYNECOLOGIC ONCOLOGY GROUP
$2,310,824American College Of Ob And Gyn · U10 · FY2002 · CA
A prospective study of critical environmental exposures in formative early life that impact lifelong health in rural US children: the New Hampshire Birth Cohort Study
$2,310,791Margaret Rita Karagas · Dartmouth College · UG3 · FY2017 · OD